Log In


NOACs in the real world

Join Dr Torben Larsen for a discussion of his comprehensive paper: Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.


Despite the wealth of evidence demonstrating their ability to save lives, oral anticoagulants – including both warfarin and NOACs – are often avoided by clinicians, owing to the fear of iatrogenic internal bleeding. However, does this actually happen? This study of patient outcomes in a real-world setting demonstrates that not only do NOACs reduce the risk of stroke, some also feature significantly lower risks of death and major bleeding compared to warfarin.

Target audience

This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.

Learning objective

After participating in this educational activity, participants will be able to:

  • Describe real-world safety and efficacy data for oral anticoagulants in patients with atrial fibrillation


This independent educational activity by NOAC Education is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.


John Camm
St George’s, University of London
Professor of Clinical Cardiology at St. George's Hospital Medical School in London
Torben Larsen
Aalborg University Hospital
Specialist Chief Physician at Aalborg University Hospital, Denmark